APOE Testing Before Starting Leqembi
Yes, APOE genotype testing should be performed prior to initiating lecanemab (Leqembi) in patients with early-stage Alzheimer's disease to inform the risk of developing amyloid-related imaging abnormalities (ARIA).
Why APOE Testing is Recommended
The FDA drug label for Leqembi explicitly states that "testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA" 1. This is not optional guidance—it is a critical safety measure embedded in the prescribing information.
ARIA Risk Stratification by APOE Genotype
The risk of ARIA varies dramatically based on APOE ε4 carrier status:
- APOE ε4 homozygotes (ε4/ε4): Highest risk group with approximately 3-8 fold increased risk of ARIA-E compared to non-carriers 2, 3
- APOE ε4 heterozygotes (one ε4 allele): Intermediate risk with approximately 1.5-fold increased risk 2, 3
- APOE ε4 non-carriers: Lowest baseline risk for ARIA
In the Clarity AD trial, ARIA-E occurred in approximately 12.6% of all patients, but this masks substantial genotype-driven variation 4. Recent real-world data from the K-ROAD study showed ARIA-E incidence of 2.0% in non-carriers versus 6.2% in ε4/ε4 homozygotes 2.
Clinical Implementation
Pre-Treatment Workflow
- Confirm diagnosis of early AD (MCI due to AD or mild AD dementia) with biomarker evidence of amyloid pathology
- Order APOE genotyping before first infusion
- Conduct genetic counseling to discuss:
- Risk of ARIA across different genotypes
- Implications of test results for treatment decisions
- That testing cannot be "undone" once results are known 5
- Obtain informed consent specifically addressing genetic testing implications 5
What If Testing Is Not Performed?
The FDA label is clear: "if testing is not performed, it cannot be determined if they are ApoE ε4 homozygotes and at a higher risk for ARIA" 1. This creates a critical knowledge gap that prevents proper risk stratification and informed consent. Without knowing genotype status, you cannot adequately counsel patients about their individualized ARIA risk.
Important Caveats
APOE Testing Is for Safety, Not Diagnosis
Do not use APOE testing for diagnostic purposes in AD 5. APOE ε4 is a susceptibility gene, not a deterministic mutation. The 2011 ACMG/NSGC guidelines explicitly state that APOE genotyping for predictive purposes is not routinely recommended outside the context of anti-amyloid therapy 5. The current indication is specifically for treatment planning and ARIA risk assessment, not for establishing AD diagnosis 6, 7.
Genetic Counseling Requirements
APOE testing should occur within the context of genetic counseling 5. Key counseling points include:
- APOE ε4 status affects ARIA risk but does not determine whether someone will develop AD
- Results have implications for family members
- Potential for genetic discrimination (though protections exist under federal law)
- Results will be part of the medical record 5
European Regulatory Difference
Notably, the European Medicines Agency has taken a more restrictive approach, limiting lecanemab approval to patients who are NOT homozygous for APOE ε4 8. The U.S. FDA does not exclude ε4/ε4 homozygotes but requires disclosure of increased risk.
MRI Monitoring Requirements
Regardless of APOE status, all patients require:
- Baseline MRI within 12 months of treatment initiation
- Serial MRIs before the 5th, 7th, and 14th infusions
- Mandatory sequences: DWI, T2 FLAIR, and T2* GRE or SWI 4
APOE ε4 homozygotes require particularly vigilant monitoring given their elevated ARIA risk.
Bottom Line
APOE genotyping is a mandatory component of the pre-treatment evaluation for lecanemab. It enables proper risk stratification, informed consent, and individualized monitoring strategies. The test should be ordered alongside other eligibility assessments (amyloid confirmation, baseline MRI, exclusion criteria review) and results discussed through genetic counseling before the first infusion 1, 9.